Composing a Tumor Specific Bacterial Promoter
Overview
Affiliations
Systemically applied Salmonella enterica spp. have been shown to invade and colonize neoplastic tissues where it retards the growth of many tumors. This offers the possibility to use the bacteria as a vehicle for the tumor specific delivery of therapeutic molecules. Specificity of such delivery is solely depending on promoter sequences that control the production of a target molecule. We have established the functional structure of bacterial promoters that are transcriptionally active exclusively in tumor tissues after systemic application. We observed that the specific transcriptional activation is accomplished by a combination of a weak basal promoter and a strong FNR binding site. This represents a minimal set of control elements required for such activation. In natural promoters, additional DNA remodeling elements are found that alter the level of transcription quantitatively. Inefficiency of the basal promoter ensures the absence of transcription outside tumors. As a proof of concept, we compiled an artificial promoter sequence from individual motifs representing FNR and basal promoter and showed specific activation in a tumor microenvironment. Our results open possibilities for the generation of promoters with an adjusted level of expression of target proteins in particular for applications in bacterial tumor therapy.
Engineered Bacteria for Disease Diagnosis and Treatment Using Synthetic Biology.
Jin K, Huang Y, Che H, Wu Y Microb Biotechnol. 2025; 18(1):e70080.
PMID: 39801378 PMC: 11725985. DOI: 10.1111/1751-7915.70080.
Deyneko I Int J Mol Sci. 2024; 25(3).
PMID: 38339181 PMC: 10856692. DOI: 10.3390/ijms25031903.
Guidelines on the performance evaluation of motif recognition methods in bioinformatics.
Deyneko I Front Genet. 2023; 14:1135320.
PMID: 36824436 PMC: 9941176. DOI: 10.3389/fgene.2023.1135320.
Engineering bacteria for cancer therapy.
Harimoto T, Danino T Emerg Top Life Sci. 2021; 3(5):623-629.
PMID: 33523173 PMC: 8056215. DOI: 10.1042/ETLS20190096.
Engineering the gut microbiota to treat chronic diseases.
Dosoky N, May-Zhang L, Davies S Appl Microbiol Biotechnol. 2020; 104(18):7657-7671.
PMID: 32696297 PMC: 7484268. DOI: 10.1007/s00253-020-10771-0.